Conditions: Lupus Nephritis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 13
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in mainland Chinese subjects with systemic lupus erythematosus (SLE)

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: Open-label long-term extension phase

Interventions: intervention 1: Placebo intervention 2: Abatacept intervention 3: Abatacept
Intervention descriptions: intervention 1: Infusion, Intravenous, single dose, Day 1 intervention 2: Infusion, Intravenous, 30mg/kg, single dose, Day 1 intervention 3: Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study

Protocol document: